10-K: Niagen Bioscience Reports Strong 2025 Growth, Strategic Shifts

Niagen Bioscience, Inc. reported significant revenue and net income growth in 2025, driven by strong Tru Niagen and ingredient sales, alongside strategic intellectual property and segment divestiture actions.

Summary

• Niagen Bioscience, Inc. (formerly ChromaDex Corporation) changed its name and ticker symbol to NAGE, reflecting its focus as a global bioscience company dedicated to healthy aging and nicotinamide adenine dinucleotide (NAD+) research.
• The company commercializes food-grade Niagen (nicotinamide riboside chloride, NRC) as a dietary and food ingredient, and launched its Tru Niagen dietary supplement in 2017.
• In 2024, Niagen Plus products, featuring pharmaceutical-grade Niagen, were launched and are supplied to U.S. FDA-registered 503B outsourcing facilities and compounding pharmacies abroad for prescription use.
• Niagen Bioscience holds a robust portfolio of owned and exclusively licensed patents related to Niagen and other NAD+ precursors, supported by over 300 research collaborations and 41 published human clinical trials on Niagen's safety and efficacy.
• Total net sales increased 30% to $129.4 million in 2025 from $99.6 million in 2024, representing an 18% compound annual growth rate from 2021 to 2025.
• Net income surged 103% to $17.4 million in 2025, up from $8.55 million in 2024.
• The company sold its analytical reference standards and services segment for approximately $6.0 million (less $0.2 million in working capital adjustments) in February 2026, streamlining its business focus.
• In December 2025, Niagen Bioscience acquired full ownership of certain patent rights from Queens University Belfast (QUB), settling $3.5 million in accrued royalties for $1.5 million and recognizing a $2.0 million gain.
• A $10.0 million revolving credit facility with Western Alliance Bank had no outstanding borrowings as of December 31, 2025.
• A share repurchase program of up to $10.0 million was approved in November 2025, with $0.3 million in shares repurchased by December 31, 2025.
• The company filed a complaint against the FDA in February 2026, challenging the regulatory status of nicotinamide mononucleotide (NMN).
• California litigation with Elysium Health, Inc. was settled for $2.65 million, with payments received by March 2025.
• An ongoing patent infringement appeal against Elysium Health, Inc. in Delaware carries a potential liability of approximately $10.4 million if the company is unsuccessful.
• An IRS partial disallowance of $0.2 million for Employee Retention Tax Credits for Q2 2021 was noted.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, highlighting significant financial growth, strategic intellectual property gains, and a clear path for future product development in growing markets. The company's improved profitability and cash position are notable, despite ongoing legal and competitive challenges.

Positives

• Total net sales increased 30% to $129.4 million in 2025 from $99.6 million in 2024, demonstrating strong top-line growth.
• Net income increased 103% to $17.4 million in 2025 from $8.55 million in 2024, indicating improved profitability.
• Gross profit increased 35% to $83.2 million in 2025, with the overall gross margin percentage improving by 250 basis points to 64.3%.
• The Consumer Products segment's sales increased 27% ($20.9 million) in 2025, driven by significant e-commerce growth ($16.2 million) and increased sales to distributor partners ($5.6 million).
• The Ingredients segment's sales increased 45% ($8.9 million) in 2025, primarily due to higher sales to existing food-grade Niagen partners ($6.6 million) and a full year of pharmaceutical-grade Niagen sales ($2.1 million).
• Operating cash flow increased to $13.5 million for the year ended December 31, 2025, up from $12.1 million in 2024, reflecting improved cash generation from operations.
• Cash and cash equivalents increased to $64.8 million as of December 31, 2025, from $44.66 million in 2024, strengthening the company's liquidity position.
• Net working capital improved significantly to $19.4 million in 2025 from $8.4 million in 2024.
• The company acquired full ownership of certain patent rights from Queens University Belfast (QUB), terminating prior royalty and license arrangements and eliminating future obligations, resulting in a $2.0 million gain on settlement.
• The California litigation with Elysium Health, Inc. was successfully settled, resulting in a payment of $2.65 million to Niagen Bioscience.
• No adverse effects have been attributed to Niagen in any of the 41 published human clinical trials, supporting its safety profile.
• Food-grade Niagen has been successfully reviewed under the FDA's new dietary ingredient (NDI) program twice and notified as Generally Recognized as Safe (GRAS).
• Pharmaceutical-grade Niagen is authorized by the FDA for compounding by 503B outsourcing facilities.
• The company maintains a strong intellectual property portfolio with over 20 owned and licensed patents listed.
• The approval of a share repurchase program of up to $10.0 million demonstrates management's confidence in the company's financial health and commitment to shareholder returns.
• The effective tax rate was 4.5% in 2025, with a reduction in the valuation allowance by approximately $3.8 million.

Negatives

• General and administrative expenses increased significantly by $8.7 million (47%) in 2025, driven by higher employee-related expenses, share-based compensation, professional/consulting fees, and increased royalty expense (due to the absence of a prior year's reversal).
• Increased investment in working capital, particularly inventory, resulted in an $11.6 million use of cash during 2025.
• The company received an IRS partial disallowance of $0.2 million for its Employee Retention Tax Credit claim for Q2 2021.
• An ongoing legal proceeding involves a complaint filed against the FDA challenging the regulatory status of nicotinamide mononucleotide (NMN), with an uncertain outcome.
• The company faces an ongoing patent infringement appeal against Elysium Health, Inc. in Delaware, with a potential liability of approximately $10.4 million (including interest) if the appeal is unsuccessful.
• A retail partner in Asia initiated a recall of Tru Niagen Immune Daily Defense product in Hong Kong and Singapore due to alleged non-compliance with Vitamin D3 labeling, potentially leading to breach of supply agreements and unquantified losses.
• The company relies on a single supplier, W.R. Grace & Co.-Conn., for food-grade NRC, and Grace holds patents that limit the company's ability to find alternative sources, posing a supply chain risk.
• The company has a history of aggregate operating losses totaling $164.5 million from inception through December 31, 2025, despite recent profitability.
• There is a significant concentration of outstanding trade receivables, with approximately 34% of the total aggregated among two customers as of December 31, 2025.

Risks

• Interruptions in relationships or declines in business with major customers could materially harm business and financial results.
• Global, market, and economic conditions (e.g., inflation, tariffs, trade disputes, geopolitical issues, interest rates, unstable credit markets) may negatively impact business, financial condition, and share price.
• Future success largely depends on sales of the Tru Niagen product; inability to expand market acceptance and increase consumer awareness is critical.
• The success of the consumer product and ingredient business is linked to the size and growth rate of the wellness industry market, and an adverse change could have a material adverse effect.
• The future growth and profitability of the consumer product business depend on the effectiveness and efficiency of marketing efforts.
• Many competitors are larger and have greater financial and other resources.
• The company has a history of operating losses and may need additional financing to meet future long-term capital requirements, potentially being unable to raise sufficient capital on favorable terms or at all.
• Operating results may fluctuate significantly, making future results difficult to predict and potentially causing results to fall below expectations.
• Inability to maintain or develop sales, marketing, and distribution capabilities or arrangements with third parties to sell, market, and distribute products may harm the business.
• Business could be negatively impacted by cybersecurity incidents or threats, leading to data breaches, material interruptions to operations, manufacturing or laboratory systems, clinical trials, and IT systems, and violations of privacy/data security obligations.
• The company may need to increase the size of its organization and may not successfully expand operations or manage growth effectively.
• The insurance industry may become more selective in offering some types of coverage, potentially limiting future availability or increasing costs.
• Dependence on key personnel; the loss of any could negatively affect the business.
• The company may not be able to monetize its products for use in pharmaceuticals through partnerships, licensing, or other arrangements, and may not receive regulatory approval to commercialize a pharmaceutical product.
• The company may not be successful in acquiring complementary businesses or products on favorable terms or entering into joint venture or similar arrangements.
• A significant disruption in information technology systems or failure to implement new systems successfully could adversely affect the business.
• The company is subject to financial and operating covenants in its business financing agreement with Western Alliance Bank; failure to comply could limit borrowing availability and materially adversely impact liquidity.
• The company is subject to potential payment processing risk.
• Reliance on a single supplier, W.R. Grace, for NRC and a limited number of third-party suppliers for raw materials; any failure or loss of a supplier could result in delays and increased costs.
• Failure by outsourcing facilities that produce pharmaceutical-grade Niagen and related finished products to adequately perform their obligations could harm the business or financial results.
• Any failure by clinics administering Niagen Plus products could adversely affect the brand and reputation.
• Unfavorable publicity or consumer perception of products and any similar products distributed by other companies could have a material adverse effect on the business.
• The company may incur material product liability claims or class action litigation, which could increase costs and adversely affect reputation, revenues, and operating income.
• Utilization of ingredients and components from foreign suppliers may be negatively affected by risks associated with international trade and importation issues.
• The company may experience delays in the development of, or may never develop, any additional products to commercialize.
• The company may not be able to partner with others for technological capabilities and new products and services.
• Failure to maintain adequate quality standards for products and services could adversely affect business and harm reputation.
• Product recalls could result in significant and unexpected costs, and adversely affect business reputation.
• Demand for products and services is subject to the commercial success of customers' products, which may vary for reasons outside the company's control.
• Ability to protect intellectual property and proprietary technology through patents and other means is uncertain and may be inadequate.
• Patents and licenses may be subject to challenge on validity grounds, and patent applications may be rejected.
• The company may become subject to claims of infringement or misappropriation of the intellectual property rights of others, which could prohibit product development, require licenses, or result in substantial monetary damages.
• The prosecution and enforcement of patents licensed from third parties are not within the company's control.
• The company may be subject to damages resulting from claims that it, its employees, or independent contractors have wrongfully used or disclosed alleged trade secrets of others.
• Changes in government regulation, priorities, or practices relating to the pharmaceutical, dietary supplement, food, and cosmetic industry could affect compliance and demand for products and services.
• Compliance with stringent and changing global privacy and data security laws and regulations may increase operating costs, expose to liability, and restrict data processing.
• The company is subject to regulation by various federal, state, local, and foreign agencies; failure to comply could subject it to fines, penalties, and additional costs.
• Reliance on outsourcing facilities for pharmaceutical-grade Niagen; removal from FDA's interim list or failure to be placed on the final list could lead to additional regulatory scrutiny.
• There is no guarantee that the IND application for AT treatment will be successful, or that clinical trials or FDA approval will be achieved.
• Government regulations of customers' businesses are extensive and constantly changing, which can significantly affect customer demand for products and services.
• Changes in government regulation related to regulatory approvals to market and sell goods could adversely affect the ability to generate revenues.
• The market price of common stock may be volatile and adversely affected by several factors.
• The company has not paid cash dividends in the past and does not expect to in the foreseeable future; any return on investment may be limited to the value of common stock.
• A significant number of outstanding options, unvested restricted stock units, and unvested market performance stock units; future sales could adversely affect the market price of common stock.
• Ability to use net operating loss (NOL) carryforwards and certain other tax attributes may be limited.
• Bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes, which could limit stockholders' ability to obtain a favorable judicial forum.
• The company may become involved in securities class action litigation that could divert management's attention and harm the business.
• Failure to establish and maintain effective internal control over financial reporting could result in material misstatements, failure to meet reporting obligations, and loss of investor confidence.
• The company has a limited operating history in China, and its ability to develop successful channels there is subject to legal, political, economic, and social uncertainties.
• Environmental, social, and governance (ESG) matters and any related reporting obligations may impact the business and reputation.
• Changes in tax laws or regulations that are applied adversely to the company or its customers may have a material adverse effect on business, cash flow, financial condition, or results of operations.
• Shares of common stock may be thinly traded, potentially making it difficult to sell at or near ask prices or at all.
• Stockholders may experience significant dilution if future equity offerings are used to fund operations or acquire complementary businesses.

Future Outlook

The company anticipates continued increases in operating expenses as it develops its sales, marketing, distribution, and commercial infrastructure, and continues to develop and commercialize its products. While existing cash resources and available borrowings are believed to be sufficient for current operating plans for at least the next twelve months and beyond, additional funds may be required for strategic investments or growth opportunities. There is no assurance that pharmaceutical development efforts will result in successful clinical outcomes, regulatory approval, or commercial success, nor can the company predict the impact of potential future legislation or regulations. The company also cannot guarantee that future scientific research, findings, or media attention will be favorable to the dietary supplement market or its products, or that comparable insurance coverage will be available on favorable terms. The ability to attract and retain qualified employees and successfully integrate new acquisitions or partnerships is also uncertain. The market price of common stock may remain volatile, and the company does not expect to pay cash dividends in the foreseeable future.

Management Comments

• Our management concluded that our disclosure controls and procedures were effective as of December 31, 2025.
• Our management concluded that, as of December 31, 2025, our internal control over financial reporting was effective in providing reasonable assurance regarding the reliability of financial reporting.
• We believe that our existing cash resources and available borrowings are sufficient to fund our current operating plans for at least the next twelve months.
• We believe that our current unrestricted cash and cash equivalents, together with cash expected to be generated from operations will be sufficient to meet our financial obligations as they become due over at least the next twelve months and beyond.
• We believe our employee relations are good.
• We believe our products are following all applicable regulations in those jurisdictions within which they are sold or marketed.
• The Company believes the Court abused its discretion in granting the award [of attorneys' fees to Elysium].
• The Company believes it has complied with its contractual obligations and applicable regulatory requirements and intends to defend itself vigorously [regarding the Tru Niagen Immune Daily Defense recall].
• The Company does not believe that the ultimate resolution of this matter [sublicense fees] will be material to the Company’s results of operations, financial condition or cash flows.
• The Company has determined that the current concentration [of trade receivables] is primarily due to the timing of purchases, and the Company does not consider the concentration of its trade receivables to be a significant risk.

Industry Context

StockSavvy.ai notes that Niagen Bioscience's strong growth in the consumer products and ingredients segments aligns with the projected expansion of the global wellness industry, estimated at $6.8 trillion in 2024 and expected to grow 7.6% annually to 2029. The dietary supplements market, valued at $193 billion in 2024 with an 8.9% CAGR to 2033, and the intravenous hydration therapy market, at $3 billion in 2024 with a 9.0% CAGR, provide favorable tailwinds for the company's core offerings. The company's focus on NAD+ research and its proprietary Niagen ingredient positions it well within the anti-aging and cellular health niche, a growing area within the broader wellness market. However, the increasing competition, including recent FDA decisions regarding NMN, highlights the dynamic regulatory and competitive landscape in which Niagen Bioscience operates.

Comparison to Industry Standards

• The global dietary supplements market size was estimated at $193 billion in 2024, and is expected to grow at a compound annual growth rate of 8.9% from 2025 to 2033. Niagen Bioscience's total net sales grew by 19% in 2024 and 30% in 2025, with a compound annual growth rate of 18% from 2021 to 2025, significantly outpacing the projected industry growth rate.
• The intravenous hydration therapy market size was estimated at $3 billion in 2024, and is expected to grow at a compound annual growth rate of 9.0% from 2025 to 2033. Niagen Bioscience's launch of pharmaceutical-grade Niagen for IV and injectable formulations positions it to capitalize on this growth, though specific revenue from this new offering is not yet disaggregated to allow for direct comparison.
• The company's 41 published human clinical trials on its proprietary ingredient Niagen demonstrating safety and/or efficacy, and over 525 published human clinical studies related to NAD+, indicate a strong commitment to scientific validation. This level of research support is generally considered robust compared to many smaller competitors in the dietary supplement space, which often lack extensive clinical backing.
• The company's reliance on a single supplier (W.R. Grace & Co.-Conn.) for food-grade NRC, with Grace holding patents on the crystalline form, presents a supply chain risk. While common for companies with highly proprietary ingredients, this could be a vulnerability compared to larger pharmaceutical or consumer goods companies with diversified sourcing strategies or in-house manufacturing capabilities.

Corporate Governance

Legal Proceedings

• **U.S. Food and Drug Administration:** On February 3, 2026, Niagen Bioscience Inc. filed a complaint against the FDA in the U.S. District Court for the District of Columbia, challenging the FDA's September 2025 response letters concerning the regulatory status of nicotinamide mononucleotide (NMN). The company seeks declaratory and injunctive relief, not monetary damages, and the outcome is uncertain.
• **Elysium Health, LLC (California Action):** Litigation commenced on December 29, 2016, was fully resolved through a binding settlement agreement on December 24, 2024. Elysium paid $2,650,000 to Niagen Bioscience in two equal installments by March 28, 2025, and the judgment was fully satisfied on April 4, 2025.
• **Elysium Health, LLC (Delaware Patent Infringement Action):** An ongoing appeal to the U.S. Court of Appeals for the Federal Circuit concerns a final judgment of $9.2 million (plus judgment interest, totaling approximately $10.4 million) in attorneys' fees and costs granted to Elysium. Niagen Bioscience believes the court abused its discretion, and no accrual has been recorded as the ultimate resolution remains uncertain.
• **Contingencies (Sublicense Fees):** In September 2019, the company received a letter from a licensor claiming $1.6 million plus interest for sublicense fees. The company believes it does not owe these fees and does not expect the ultimate resolution to be material to its financial results.
• **Contingencies (Product Recall):** In December 2025, a retail partner in Asia initiated a recall of Tru Niagen Immune Daily Defense product due to alleged non-compliance with Vitamin D3 labeling. In February 2026, the retail partner alleged breach of supply agreements and is quantifying losses. The company believes it complied with obligations and intends to defend itself vigorously; a loss is reasonably possible, but the amount cannot be reasonably estimated.

Related Party Transactions

• A.S. Watson Group was considered a related party prior to August 20, 2024, due to common ownership by an enterprise that beneficially owned more than 10% of the company's common stock. This entity sold its ownership on August 20, 2024, after which A.S. Watson Group ceased to be a related party.
• Sales of consumer products to A.S. Watson Group totaled $8.7 million for the year ended December 31, 2024 (excluding sales after August 20, 2024).
• There were no trade receivables connected to related parties as of December 31, 2025, and December 31, 2024.

Stakeholder Impact

• **Shareholders:** Potential for dilution from future equity offerings, market price volatility, and no expected cash dividends in the foreseeable future. However, the share repurchase program could provide a benefit by reducing outstanding shares. Strong financial performance and strategic moves could positively impact share value.
• **Employees:** Benefit from the Employee Stock Purchase Plan (ESPP) and share-based compensation plans. The company's focus on attracting and retaining talent, along with good employee relations, supports a stable workforce.
• **Customers:** Benefit from the company's commitment to product quality, scientific support, and regulatory compliance. Expansion of Tru Niagen and Niagen Plus offerings provides more choices. However, potential product recalls or negative publicity could impact customer trust.
• **Suppliers:** The company's reliance on a single supplier (W.R. Grace) for NRC creates a concentration risk, potentially affecting supply stability and pricing. Other third-party manufacturers and suppliers are also critical to operations.
• **Creditors:** The company's strong cash position ($64.8 million) and no outstanding borrowings on its $10.0 million credit facility as of December 31, 2025, indicate a healthy financial standing. However, the company is subject to financial and operating covenants if it draws from the credit line.

Next Steps

• Continue research and development of NAD+ precursors for potential therapeutic applications in advanced aging rare diseases.
• Pursue an investigational new drug (IND) application with the FDA for Ataxia Telangiectasia (AT) treatment.
• Evaluate opportunities to enter additional international markets for Tru Niagen products.
• Continue to work with U.S. FDA-registered 503B outsourcing facilities and collaborate with clinics for pharmaceutical-grade Niagen.
• Provide certain operational and administrative services to the buyer of the analytical reference standards and services segment for up to six months following the closing date (February 24, 2026).
• Continue to monitor the creditworthiness and payment behavior of major customers.
• Continue to pursue new partnerships and business opportunities to diversify the customer base.
• Continue to analyze the potential impact of any additional transactions undertaken upon the utilization of net operating losses.
• The first offering period under the Employee Stock Purchase Plan (ESPP) commenced on January 1, 2026.
• The share repurchase program is active and expires on October 31, 2027.
• The revolving credit facility with Western Alliance Bank matures on November 12, 2027.
• The initial term of the supply agreement with W.R. Grace & Co.-Conn. expires on April 30, 2029, with automatic renewals unless notice is given.
• Ongoing appeal of the Delaware patent infringement case against Elysium Health, Inc. to the U.S. Court of Appeals for the Federal Circuit.

Key Dates

Recommendation

Niagen Bioscience demonstrated exceptional financial performance in 2025 with a 30% increase in net sales and a 103% surge in net income, significantly outperforming industry growth rates. The company's strategic acquisition of key patent rights and divestiture of a non-core segment streamline its focus on the high-growth NAD+ market. While legal challenges and supplier concentration exist, the strong cash position, share repurchase program, and robust scientific validation of its core products suggest a positive trajectory for long-term value creation.

Keywords

Niagen Bioscience, NAD+, Nicotinamide Riboside Chloride, NRC, Tru Niagen, Dietary Supplements, Healthy Aging, Pharmaceutical-grade Niagen, FDA, SEC Filing, 10-K, Bioscience, Health & Wellness, Intellectual Property, Corporate Governance, Financial Performance, Stock Repurchase, Legal Proceedings, Patent Infringement, Employee Retention Tax Credit, NMN